Inside EP: Insights From Clinical Decision-Makers for the Industry Professional-Recent and Upcoming Trials in Heart Failure

Video Transcription

Video Summary

The video transcript highlights the importance of pharmaceuticals, sensors, AI, and electroceuticals in changing the paradigm of heart failure treatment. There are numerous clinical trials currently underway, focusing on different aspects of heart failure management. The use of pharmaceuticals such as neprolisin inhibitors and SGLT2 inhibitors has shown promising results in improving outcomes and reducing mortality. Other drugs and signaling pathways are being investigated, including direct sarcomere activators and soluble guanylide cyclase stimulators. Device therapy, such as cardiac resynchronization therapy (CRT), is also being studied, with a focus on optimizing lead placement and pacing strategies. Neuromodulation techniques, including vagal nerve stimulation and carotid baroreceptor stimulation, are being explored as potential treatment options. Machine learning algorithms are being used to classify patients and identify those who are most likely to benefit from specific treatments. The future of heart failure management lies in a multidisciplinary approach and strategy trials to assess the effectiveness of different interventions.

Asset Caption

Jagmeet P. Singh, MD, PhD, FHRS, Massachusetts General Hospital, Boston, MA

Keywords

pharmaceuticals

sensors

AI

electroceuticals

heart failure treatment